Pharmacokinetics and pharmacokinetic/pharmacodynamic associations of ofatumumab, a human monoclonal CD20 antibody, in patients with relapsed or refractory chronic lymphocytic leukaemia: a phase 1–2 study.

MLA

Coiffier, Bertrand, et al. “Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Associations of Ofatumumab, a Human Monoclonal CD20 Antibody, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukaemia: A Phase 1–2 Study.” British Journal of Haematology, vol. 150, no. 1, July 2010, pp. 58–71. EBSCOhost, https://doi.org/10.1111/j.1365-2141.2010.08193.x.

APA

Coiffier, B., Losic, N., Rønn, B. B., Lepretre, S., Pedersen, L. M., Gadeberg, O., Frederiksen, H., van Oers, M. H. J., Wooldridge, J., Kloczko, J., Holowiecki, J., Hellmann, A., Walewski, J., Robak, T., & Petersen, J. (2010). Pharmacokinetics and pharmacokinetic/pharmacodynamic associations of ofatumumab, a human monoclonal CD20 antibody, in patients with relapsed or refractory chronic lymphocytic leukaemia: a phase 1–2 study. British Journal of Haematology, 150(1), 58–71. https://doi.org/10.1111/j.1365-2141.2010.08193.x

Chicago

Coiffier, Bertrand, Nedjad Losic, Birgitte Biilmann Rønn, Stéphane Lepretre, Lars Møller Pedersen, Ole Gadeberg, Henrik Frederiksen, et al. 2010. “Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Associations of Ofatumumab, a Human Monoclonal CD20 Antibody, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukaemia: A Phase 1–2 Study.” British Journal of Haematology 150 (1): 58–71. doi:10.1111/j.1365-2141.2010.08193.x.